Tilray Medical Receives Approval for First Medical Cannabis Extract
in Portugal
CANTANHEDE, Portugal, March 14, 2024 (GLOBE
NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”)
(Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer
packaged goods company inspiring and empowering the worldwide
community to live their very best life, today announced a
groundbreaking achievement in the medical cannabis industry in
Portugal. Following the successful approval of our Tilray whole
flower THC 18, Tilray Medical has now received approval for the
first medical cannabis extract, Tilray Oral Solution THC 5 CBD 20,
in Portugal, marking a significant milestone in medical cannabis
availability and patient care within the country.
Denise Faltischek, Chief Strategy Officer and
Head of International at Tilray Brands, Inc., said: "This is a
monumental step forward for patient care in Portugal. With the
approval of our first medical cannabis extract, we are proud to be
at the forefront of medical cannabis research and accessibility and
continue to demonstrate our commitment to providing innovative,
safe, and effective therapeutic options to patients. We continue to
pioneer the future of medical cannabis, furthering our mission to
empower and inspire individuals to live their best lives."
This landmark approval, confirmed on March 11,
2024, underscores Tilray's commitment to expanding safe and
regulated access to medical cannabis for patients in need. The
newly approved medical cannabis extract is set to launch in late
spring, offering new therapeutic options for patients across
Portugal with specified medical conditions. The approved extract is
indicated for use in several critical areas of patient care.
Tilray Medical continues to be a global leader
in the medical cannabis industry, offering a diverse portfolio of
EU-GMP certified medicinal cannabis products. With operations
extending over 20 countries, Tilray Medical is dedicated to
supporting medical cannabis patient care worldwide through quality
products accessible via healthcare practitioners.
About Tilray Medical
Tilray Medical is dedicated to transforming
lives and fostering dignity for patients in need through safe and
reliable access to a global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, Symbios, and Navcora.
Tilray Medical grew from being one of the first companies to become
an approved licensed producer of medical cannabis in Canada to
building the first GMP-certified cannabis production facilities in
Europe, first in Portugal and later in Germany. Today, Tilray
Medical is one of the biggest suppliers of medical cannabis brands
to patients, physicians, hospitals, pharmacies, researchers, and
governments, in over 20 countries and across five
continents.
Further information can also be found on the
Tilray Medical Europe website or Tilray Medical Portugal.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY;
TSX: TLRY), is a leading global cannabis lifestyle and consumer
packaged goods company with operations in Canada, the United
States, Europe, Australia, and Latin America that is changing
people's lives for the better – one person at a time – by inspiring
and empowering a worldwide community to live their very best life,
enhanced by moments of connection and wellbeing. Tilray’s mission
is to be the most responsible, trusted and market leading cannabis
consumer products company in the world with a portfolio of
innovative, high-quality, and beloved brands that address the needs
of the consumers, customers, and patients we serve. A pioneer in
cannabis research, cultivation, and distribution, Tilray’s
unprecedented production platform supports over 20 brands in over
20 countries, including comprehensive cannabis offerings,
hemp-based foods, and craft beverages.
For more information on how we open a world of
wellbeing, visit, Tilray.com and follow @Tilray on all social
platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical
facts constitute forward-looking information or forward-looking
statements (together, “forward-looking statements”) under Canadian
securities laws and within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that are intended to
be subject to the “safe harbor” created by those sections and other
applicable laws. Forward-looking statements can be identified by
words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections, or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current
expectations concerning, among other things, the Company’s ability
to grow market share and increase revenue opportunities in Germany
and across Europe. Many factors could cause actual results,
performance, or achievement to be materially different from any
forward-looking statements, and other risks and uncertainties not
presently known to the Company or that the Company deems immaterial
could also cause actual results or events to differ materially from
those expressed in the forward-looking statements contained herein.
For a more detailed discussion of these risks and other factors,
see the most recently filed annual information form of Tilray and
the Annual Report on Form 10-K (and other periodic reports filed
with the SEC) of Tilray made with the SEC and available on EDGAR.
The forward-looking statements included in this communication are
made as of the date of this communication and the Company does not
undertake any obligation to publicly update such forward-looking
statements to reflect new information, subsequent events, or
otherwise unless required by applicable securities laws.
Contacts
For media inquiries, please
contact:
Berrin Noorata
news@tilray.com
For investor inquiries, please
contact:
Raphael Gross 203-682-8253
Raphael.Gross@icrinc.com
Tilray (LSE:0Z6Y)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Tilray (LSE:0Z6Y)
Gráfica de Acción Histórica
De May 2023 a May 2024